[BLCM] Bellicum Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 14.61 Change: 0.99 (7.27%)
Ext. hours: Change: 0 (0%)

chart BLCM

Refresh chart

Strongest Trends Summary For BLCM

BLCM is in the medium-term down -70% below S&P in 1 year. In the long-term down -89% below S&P in 2 years and down -97% below S&P in 5 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-2.81 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -93.99% Sales Growth - Q/Q-93.99% P/E-4.03
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-43.58% ROE-44.27% ROI
Current Ratio69.87 Quick Ratio Long Term Debt/Equity Debt Ratio0.01
Gross Margin Operating Margin-3029.56% Net Profit Margin-4346.19% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-10 K Cash From Investing Activities-930 K Cash From Operating Activities-7.03 M Gross Profit
Net Profit-7.76 M Operating Profit-7.81 M Total Assets188.27 M Total Current Assets185.01 M
Total Current Liabilities2.65 M Total Debt Total Liabilities2.91 M Total Revenue110 K
Technical Data
High 52 week7.23 Low 52 week1.08 Last close1.08 Last change-8.47%
RSI21.25 Average true range0.12 Beta1.54 Volume289.04 K
Simple moving average 20 days-26.41% Simple moving average 50 days-37.02% Simple moving average 200 days-64.52%
Performance Data
Performance Week-21.74% Performance Month-37.21% Performance Quart-65.05% Performance Half-66.97%
Performance Year-82.32% Performance Year-to-date-63.01% Volatility daily3.93% Volatility weekly8.79%
Volatility monthly18.01% Volatility yearly62.37% Relative Volume166.33% Average Volume644.42 K
New High New Low

News

2020-06-01 10:45:02 | Top Ranked Momentum Stocks to Buy for June 1st

2020-05-29 16:06:38 | Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2020-05-27 16:05:10 | Bellicum Announces Publication of Data for GoCAR-NK™ Cell Program

2020-05-27 07:30:10 | Bellicum to Participate in Two Upcoming Virtual Investor Conferences

2020-05-22 12:00:04 | All You Need to Know About Bellicum Pharmaceuticals BLCM Rating Upgrade to Strong Buy

2020-05-07 16:05:10 | Bellicum Reports First Quarter 2020 Financial Results and Provides Operational Update  

2020-05-06 10:29:20 | The Bellicum Pharmaceuticals NASDAQ:BLCM Share Price Is Down 98% So Some Shareholders Are Very Salty

2020-04-30 16:09:28 | Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2020-04-17 14:44:57 | Houston pharma co. completes $15M facility sale to M.D. Anderson as drug research stalls

2020-04-15 07:30:10 | Bellicum Completes Sale of Houston Facility

2020-03-29 11:41:04 | Edited Transcript of BLCM earnings conference call or presentation 12-Mar-20 9:00pm GMT

2020-03-12 16:05:10 | Bellicum Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Operational Update

2020-03-12 15:00:00 | Startek, Inc. to Host Earnings Call

2020-03-12 15:00:00 | Bellicum Pharmaceuticals, Inc. to Host Earnings Call

2020-03-10 06:48:56 | Bellicum Pharmaceuticals, Inc. NASDAQ:BLCM Insiders Increased Their Holdings

2020-03-05 07:30:10 | Bellicum to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Corporate Update

2020-03-03 12:30:05 | Bellicum Pharmaceuticals BLCM May Report Negative Earnings: Know the Trend Ahead of Q4 Release

2020-02-28 16:08:31 | Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2020-02-07 09:42:43 | Houston biotech firm raises millions; pharma co. enacts reverse stock split

2020-02-05 12:45:10 | Bellicum Announces Reverse Stock Split

2020-02-02 07:00:00 | Activist Investors Made Moves in Trinity Industries, B. Riley, Axonics

2020-01-31 16:05:10 | Bellicum Reports Inducement Grant Under Nasdaq Listing Rule 5635c4

2020-01-31 11:15:00 | SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Bellicum Pharmaceuticals, Inc.- BLCM

2020-01-25 09:25:07 | Here's What We Think About Bellicum Pharmaceuticals, Inc.'s NASDAQ:BLCM CEO Pay

2020-01-24 07:30:10 | Bellicum Presents New Translational Data for BPX-601 at ASCO GI Cancers Symposium

2020-01-22 09:33:25 | Houston pharma co. to sell facility to MD Anderson Cancer Center

2020-01-21 07:30:10 | Bellicum Pharmaceuticals Enters into Asset Purchase and Master Services Agreements with MD Anderson

2020-01-16 07:30:10 | Bellicum Pharmaceuticals to Present New Translational Data for BPX-601 at ASCO 2020 Gastrointestinal Cancers Symposium

2019-12-13 14:45:58 | Hedge Funds Are Betting On Bellicum Pharmaceuticals Inc BLCM

2019-12-11 07:30:10 | Bellicum Pharmaceuticals Licenses Its CaspaCIDe® Safety Switch to MD Anderson

2019-12-10 06:42:55 | Is Bellicum Pharmaceuticals, Inc. NASDAQ:BLCM A Volatile Stock?

2019-11-22 22:50:00 | BELLICUM INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Bellicum Pharmaceuticals, Inc. - BLCM

2019-11-08 07:00:00 | Bellicum Pharmaceuticals Presents Encouraging Preclinical Data for GoCAR-NK Cell Program at Society for Immunotherapy of Cancer Annual Meeting

2019-11-07 02:53:36 | Edited Transcript of BLCM earnings conference call or presentation 6-Nov-19 10:00pm GMT

2019-11-06 19:15:12 | Bellicum Pharmaceuticals BLCM Reports Q3 Loss, Lags Revenue Estimates

2019-11-06 16:15:00 | Bellicum Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Operational Update

2019-10-31 16:05:05 | Bellicum Pharmaceuticals Announces Presentation on CAR-NK Cell Program at SITC 2019

2019-10-30 07:30:05 | Bellicum Pharmaceuticals to Report Third Quarter 2019 Financial Results and Provide Corporate Update

2019-10-29 10:33:02 | Earnings Preview: Bellicum Pharmaceuticals BLCM Q3 Earnings Expected to Decline

2019-10-26 08:57:17 | Introducing Bellicum Pharmaceuticals NASDAQ:BLCM, The Stock That Tanked 95%

2019-09-30 16:07:56 | Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2019-09-23 10:54:02 | Top Ranked Momentum Stocks to Buy for September 23rd

2019-09-03 14:53:12 | Do Insiders Own Lots Of Shares In Bellicum Pharmaceuticals, Inc. NASDAQ:BLCM?

2019-08-30 16:08:07 | Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2019-08-28 16:05:00 | Bellicum Pharmaceuticals to Participate in Three Healthcare Investor Conferences during September

2019-08-21 16:05:00 | Bellicum Pharmaceuticals Announces Aggregate Gross Proceeds of $69.6 Million from $139.6 Million Public Offering and Private Placement

2019-08-20 15:47:19 | Houston pharma co. raises $69.6M through public offering, private placement

2019-08-20 15:47:19 | Houston pharma co. raising $139.6M through public offering, private placement

2019-08-16 10:56:15 | CORRECTING and REPLACING -Bellicum Pharmaceuticals, Inc.

2019-08-16 08:30:00 | Bellicum Pharmaceuticals Announces Pricing of Bellicum Pharmaceuticals Announces Pricing of $139.6 Million Public Offering and Private Placement